Call us now:
The industry’s focus is on living organisms, and the strict controlled standards make it a unique concern for business leaders. These features make the industry an ideal platform for innovation. They have produced major breakthroughs in the production of biofuels and agricultural yields and life-saving pharmaceuticals.
Biotech startups have a myriad of options when it comes down to revenue generation strategies, with the majority choosing either a technology partnership or an asset creation and out-licensing strategy. Technology-based partnerships can produce more revenue and lower risk to the financials, whereas outlicensing and asset creation strategies can yield more returns. A growing number of biotechs that are in research phase operate a hybrid model that combines both approaches.
If you choose to go with a product-oriented strategy can achieve commercial success as long as they are able to bring their pipelines to the right place, and attract a big pharmaceutical partner or an investor with a large sum of money. This can be an expensive option. It is crucial to balance opportunistic approaches in using outside resources and making right scientific decisions regarding the development of home-grown products.
The “platform” model is www.genotec-frankfurt.de/biotechnological-synthesis-of-remedies/ a second option to generate revenue. It’s a lower-cost option than the product-oriented development however, it comes with substantial risk. In this model biotechs develop and own their platform technology before partnering with pharma giants to develop a collection of drug discovery projects that target specific diseases (i.e. disease of x in biology). Advinus Therapeutics, among others have embraced this method.